Our article on MAIT and gd T cells after alloHCT is finally out! Please check ➡️ Journal of Clinical Immunology #bmtsm ⁦Mohamad Mohty⁩ link.springer.com/article/10.100…

1/Caribou Biosciences has presented clinical data from its ongoing CB-010 ANTLER Phase 1 trial that indicates $CRBU CB-010’s potential to rival approved autologous CAR-T cell therapy - Yescarta, for second line LBCL Cancer patients by refocusing its strategy on HLA matching. $XBI #ASCO24

Attention all ANZ (and beyond) early career cell and gene therapy folks - we are pleased to present a half day workshop for career development at the ISCT ANZ Regional Meeting in Queenstown in August. We'd love to see you there. Rajiv Khanna Guy Klamer, PhD (he/him) Madison Paton

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.10… EBMT_Cellular_Therapy Mohamad Mohty

“Our results highlight the rarity of second tumors and provide a framework for defining clonal relationships and viral vector monitoring.”

Proud of this comprehensive review published in ⁦Nature Reviews Disease Primers⁩ - This was a wonderful team effort during several months. Thank you ⁦Florent Malard⁩ ⁦, nizar jacques bahlis, P. Neri, E Terpos, N. Moukalled, VTM. Hungria, and S. Manier ⁦IACH⁩ ⁦COMy⁩

What a view from the conference venue meeting room for the #ISCTANZ24 regional meeting. Pre conference workshops today - Cell Therapy Manufacturing, FACT and ESP fireside chat. ISCT

Did I mention the view? #ISCTANZ24 Rajiv Khanna in the Cell and Gene Therapy Manufacturing Workshop. QIMR Berghofer ISCT

#ISCTANZ2024 even more spectacular today as the main meeting gets underway. In the joint ISCT AND ASSCR joint session. Here Janet Macpherson (she/her) presents data on non-viral lipid nano particles for gene editing of CD34 stem cells.

Just stopping by your timeline in case you didn’t know that the Chief Science Advisors for Australia, Canada, New Zealand, the United Kingdom, and the United States - are all women 🔥

💪